NextCure, Inc.
(NASDAQ : NXTC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.39%242.361.5%$875.72m
MRNAModerna, Inc. 5.17%150.230.0%$812.21m
VRTXVertex Pharmaceuticals, Inc. 0.26%282.521.9%$481.07m
GILDGilead Sciences, Inc. -0.32%61.611.0%$473.86m
REGNRegeneron Pharmaceuticals, Inc. -0.42%588.642.6%$469.68m
NVAXNovavax, Inc. 11.01%57.0975.7%$442.38m
ILMNIllumina, Inc. 1.55%187.223.3%$341.07m
SNSSSunesis Pharmaceuticals, Inc. -1.80%3.810.7%$266.33m
BIIBBiogen, Inc. 1.24%206.461.8%$241.01m
BNTXBioNTech SE 4.15%155.280.0%$194.91m
CRSPCRISPR Therapeutics AG 3.31%62.780.6%$165.38m
BMRNBioMarin Pharmaceutical, Inc. 0.74%83.484.2%$117.04m
EXASEXACT Sciences Corp. 2.45%40.3617.7%$93.17m
IOVAIovance Biotherapeutics, Inc. 2.99%11.370.0%$90.74m
TECHBio-Techne Corp. 0.42%348.094.5%$89.99m

Company Profile

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.